New imaging technology could predict patient response to NMD treatment

Since not all patients respond to disease or treatment in the same manner, it is of vital importance for physicians to run tests on large cohorts. When facing rare diseases such as Duchenne muscular dystrophy (DMD), however, such cohorts just don’t exist and other methods are required. Novel imaging technology developed under the BIOIMAGE-NMD project aim to fill this gap.

The project’s purpose was to enable the monitoring of patient response to novel therapies in neuromuscular diseases (NMDs), with DMD being used as a case in point. As Dr Andrew Blamire, Director of Newcastle University’s Centre for In Vivo Imaging, explains, there are two major driving factors for developing such monitoring technologies.

Further information: New imaging technology could predict patient response to NMD treatment